
Vaxcyte (PCVX) Stock Forecast & Price Target
Vaxcyte (PCVX) Analyst Ratings
Bulls say
Vaxcyte Inc. displays a positive financial outlook driven by the strong performance of its product candidates, particularly VAX-24 and VAX-31, which have shown superior immune responses compared to the current standard, PCV20, in adult populations. The company anticipates a significant mid- to long-term growth opportunity, estimating a global revenue potential exceeding $7-10 billion, supported by ongoing clinical trials that showcase robust seroresponse rates in both infants and adults. Additionally, the ongoing positive clinical data, especially regarding VAX-24 in infants, positions Vaxcyte favorably against its competitors in the next-generation pneumococcal vaccine market.
Bears say
The analysis highlights several fundamental risks associated with Vaxcyte Inc., primarily stemming from potential delays in research and development, regulatory hurdles, and disappointing clinical trial outcomes that could negatively impact efficacy or safety results. Additionally, the firm's commercial uptake may be stunted due to competition, particularly if competitor programs advance more quickly than Vaxcyte's offerings, which could hinder market position. Furthermore, despite the company's projected long-term revenue potential, any lack of alignment with national vaccine guidelines or failures in proving the safety and efficacy of its vaccine candidates in trials could significantly limit the company's commercial prospects.
This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.
Vaxcyte (PCVX) Analyst Forecast & Price Prediction
Start investing in Vaxcyte (PCVX)
Order type
Buy in
Order amount
Est. shares
0 shares